Selective Oral MEK1/2 Inhibitor Pimasertib Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors Selective Oral MEK1_2 Inhibitor Pimasertib_ A Phase I Trial in Patients with Advanced Solid Tumors RETOUR MarcGuevreguian2021-03-22T20:57:05+01:00
